Mr. Jan A Mansy, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 500 Academy St S, Ahoskie, NC 27910 Phone: 252-209-3708 Fax: 252-209-3049 |
Mackenzie Lesha Wilson, FNP-C Family Medicine Medicare: Medicare Enrolled Practice Location: 120 Health Center Dr, Ahoskie, NC 27910 Phone: 252-332-3548 |
Dr. Julian Raleigh Taylor, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 120 Health Center Dr, Ahoskie, NC 27910 Phone: 252-332-3548 Fax: 252-332-1665 |
Dr. Colin D Jones, M.D. Family Medicine Medicare: May Accept Medicare Assignments Practice Location: 120 Health Center Dr, Ahoskie, NC 27910 Phone: 252-332-3548 Fax: 252-332-1665 |
Dr. Charles Judson Sawyer Iii, M.D. Family Medicine Medicare: May Accept Medicare Assignments Practice Location: 120 Health Center Dr, Ahoskie, NC 27910 Phone: 252-332-3548 Fax: 252-332-1665 |
News Archive
IPSOGEN SA today announces that two studies on the Genomic Grade test will be presented at the American Society for Clinical Oncology Annual Meeting, that will take place June 3-7, 2011, in Chicago, Ill, USA.
A new study describes two promising small molecules that inhibit a host cell factor, called nucleotide binding oligomerization domain-containing protein 2 (NOD2), that inhibits the replication and spread of many arboviruses. This could lead to the development of broad-spectrum antivirals. The study's findings have been published on the preprint server bioRxiv*.
Study findings suggest that the impaired ability to retain and repeat unfamiliar phoneme sequences in children with specific language impairment reflects inadequate encoding of phonologic information, rather than problems retaining encoded information.
The next treatment for cancer might come from fish says a new research report published in the March 2010 print edition of the FASEB Journal (http://www.fasebj.org). In the report, scientists show that the omega-3 fatty acid, "docosahexaenoic acid" or "DHA," and its derivatives in the body kill neuroblastoma cancer cells.
Bionovo, Inc., a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, announced today that the Company's independent Data Safety Monitoring Board (DSMB) recommended that the Phase 3 trial of Menerba (MF101) could continue as designed after an initial review of its clinical safety and tolerability data.
› Verified 7 days ago